• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5081128)   Today's Articles (1155)
For: Viola A, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Cappello M. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study. World J Gastrointest Pharmacol Ther 2017; 8(2): 131-136 [PMID: 28533923 DOI: 10.4292/wjgpt.v8.i2.131] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register]  Open
Number Cited by Other Article(s)
1
Rosenthal B, Aulakh S, Patel PV, Wong JT, Ali S. Direct transition from rapid-infusion originator to rapid-infusion biosimilar tumor necrosis factor inhibitor in children with inflammatory bowel disease: A case series. Am J Health Syst Pharm 2024;81:61-65. [PMID: 37773728 PMCID: PMC11484643 DOI: 10.1093/ajhp/zxad217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Indexed: 10/01/2023]  Open
2
Rusch C, Wood M, Kennedy AG, Tompkins BJ, Frasca JD. Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease. J Clin Pharm Ther 2022;47:1851-1857. [PMID: 36134561 PMCID: PMC9825869 DOI: 10.1111/jcpt.13779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Revised: 08/26/2022] [Accepted: 09/04/2022] [Indexed: 01/11/2023]
3
Ong WC, Lim MS, Chan E, Lim TCT, Lim TG, Chan W. A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol. JGH OPEN 2022;6:470-476. [PMID: 35822121 PMCID: PMC9260204 DOI: 10.1002/jgh3.12776] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Revised: 04/29/2022] [Accepted: 05/15/2022] [Indexed: 11/11/2022]
4
O'Connell DM, Nachreiner J, Shu X, Terry E, Imburgia T, Vanderloo J, Lasarev MR, Bogenschutz M. Rapid Infliximab Biosimilar Infusion in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2022;74:605-609. [PMID: 35149648 DOI: 10.1097/mpg.0000000000003402] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
5
Pusateri A, Hatcher A, Patel N, Lehman J, Hinton A, Afzali A. Impact of rapid infliximab infusions on access at a large academic tertiary medical center. Am J Health Syst Pharm 2021;78:2046-2052. [PMID: 34050749 DOI: 10.1093/ajhp/zxab225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
6
Safety of Rapid Infliximab Infusions in Children: A Systematic Review. J Pediatr Gastroenterol Nutr 2020;71:361-365. [PMID: 32558671 DOI: 10.1097/mpg.0000000000002815] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA